InflaRx Statistics
Total Valuation
InflaRx has a market cap or net worth of $172.42 million. The enterprise value is $42.29 million.
| Market Cap | 172.42M |
| Enterprise Value | 42.29M |
Important Dates
The last earnings date was Tuesday, November 3, 2026, before market open.
| Earnings Date | Nov 3, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
InflaRx has 147.37 million shares outstanding. The number of shares has increased by 58.38% in one year.
| Current Share Class | 147.37M |
| Shares Outstanding | 147.37M |
| Shares Change (YoY) | +58.38% |
| Shares Change (QoQ) | +25.25% |
| Owned by Insiders (%) | 2.95% |
| Owned by Institutions (%) | 41.21% |
| Float | 98.11M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 1.05 |
| P/TBV Ratio | 1.05 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 7.26, with a Debt / Equity ratio of 0.01.
| Current Ratio | 7.26 |
| Quick Ratio | 7.00 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -535.36 |
Financial Efficiency
Return on equity (ROE) is -30.95% and return on invested capital (ROIC) is -21.35%.
| Return on Equity (ROE) | -30.95% |
| Return on Assets (ROA) | -18.03% |
| Return on Invested Capital (ROIC) | -21.35% |
| Return on Capital Employed (ROCE) | -22.58% |
| Weighted Average Cost of Capital (WACC) | 17.52% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$512,299 |
| Employee Count | 65 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -19.86% in the last 52 weeks. The beta is 2.42, so InflaRx's price volatility has been higher than the market average.
| Beta (5Y) | 2.42 |
| 52-Week Price Change | -19.86% |
| 50-Day Moving Average | 1.70 |
| 200-Day Moving Average | 1.66 |
| Relative Strength Index (RSI) | 31.16 |
| Average Volume (20 Days) | 1,070,989 |
Short Selling Information
The latest short interest is 12.84 million, so 9.51% of the outstanding shares have been sold short.
| Short Interest | 12.84M |
| Short Previous Month | 12.73M |
| Short % of Shares Out | 9.51% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 18.13 |
Income Statement
In the last 12 months, InflaRx had revenue of -$38,532 and -$33.30 million in losses. Loss per share was -$0.33.
| Revenue | -38,532 |
| Gross Profit | -5.56M |
| Operating Income | -37.09M |
| Pretax Income | -33.30M |
| Net Income | -33.30M |
| EBITDA | -37.09M |
| EBIT | -37.09M |
| Loss Per Share | -$0.33 |
Balance Sheet
The company has $131.05 million in cash and $920,098 in debt, with a net cash position of $130.13 million or $0.88 per share.
| Cash & Cash Equivalents | 131.05M |
| Total Debt | 920,098 |
| Net Cash | 130.13M |
| Net Cash Per Share | $0.88 |
| Equity (Book Value) | 163.64M |
| Book Value Per Share | 1.11 |
| Working Capital | 118.48M |
Cash Flow
In the last 12 months, operating cash flow was -$20.62 million and capital expenditures -$113,290, giving a free cash flow of -$20.73 million.
| Operating Cash Flow | -20.62M |
| Capital Expenditures | -113,290 |
| Depreciation & Amortization | -2,733 |
| Net Borrowing | -321,271 |
| Free Cash Flow | -20.73M |
| FCF Per Share | -$0.14 |
Margins
| Gross Margin | n/a |
| Operating Margin | 96,258.22% |
| Pretax Margin | 86,420.22% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
InflaRx does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -58.38% |
| Shareholder Yield | -58.38% |
| Earnings Yield | -27.87% |
| FCF Yield | -12.02% |
Analyst Forecast
The average price target for InflaRx is $8.41, which is 619.06% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $8.41 |
| Price Target Difference | 619.06% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 8 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
| Graham Formula Value | n/a |
| Graham Formula Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 3 |